Yong-Chan Kim
Directeur/Bestuurslid bij BAUDAX BIO, INC.
Vermogen: 50 $ op 30-04-2024
Profiel
Yong-Chan Kim is the founder and current Chief Executive Officer & Director of TeraImmune, Inc., which is founded in 2016.
He is also currently an Independent Director at Baudax Bio, Inc. since 2023.
Dr. Kim holds a doctorate degree from Chungnam National University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
07-09-2023 | 4 520 ( 16.69% ) | 50 $ | 30-04-2024 |
Actieve functies van Yong-Chan Kim
Bedrijven | Functie | Begin |
---|---|---|
BAUDAX BIO, INC. | Directeur/Bestuurslid | 03-07-2023 |
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Oprichter | 01-01-2016 |
Opleiding van Yong-Chan Kim
Chungnam National University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BAUDAX BIO, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Health Technology |